HDAC9 and cancer: We also showed that PPP inhibitors significantly reduced the stem-like surrogate markers and sensitized HDAC inhibitor induced cancer stem cells, highlighting a potential strategy to preferentially disrupt the metabolism of resistant stem-like cancer cells.